Cardio3 BioSciences announces the enrolment of the 240th patient for its CHART-1 phase III clinical trial for the treatment of heart failure

Cardio3 BioSciences announces the enrolment of the 240th patient for its CHART-1 phase III clinical trial for the treatment of heart failure

Cardio3 BioSciences will be present at Oddo Midcap Forum

Cardio3 BioSciences will be present at Oddo Midcap Forum

Cardio3 BioSciences to address American institutional investors in January at J.P. Morgan Healthcare Conference

Cardio3 BioSciences to address American institutional investors in January at J.P. Morgan Healthcare Conference

Cardio3 BioSciences announces the nomination of three Co-Principal Investigators for its CHART-2 phase III clinical trial of C-Cure® for the treatment of heart failure

Cardio3 BioSciences announces the nomination of three Co-Principal Investigators for its CHART-2 phase III clinical trial of C-Cure® for the treatment of heart failure

Cardio3 BioSciences announces Q3 2014 business update

Cardio3 BioSciences announces Q3 2014 business update

Cardio3 BioSciences acquires CorQuest Medical Inc.

Cardio3 BioSciences acquires CorQuest Medical Inc.

Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer

Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer

Joint clarification regarding agreement between Cardio3 BioSciences and Mayo Clinic

Joint clarification regarding agreement between Cardio3 BioSciences and Mayo Clinic

Cardio3 BioSciences receives authorization to enroll patients in Switzerland in its Phase III Clinical trial Chart-1

Cardio3 BioSciences receives authorization to enroll patients in Switzerland in its Phase III Clinical trial Chart-1

Cardio3 BioSciences awarded preferred access rights to all Mayo Clinic Center for Regenerative Medecine Portolio

Cardio3 BioSciences awarded preferred access rights to all Mayo Clinic Center for Regenerative Medecine Portolio

Cardio3 BioSciences announces new business development strategy to broaden its product pipeline

Cardio3 BioSciences announces new business development strategy to broaden its product pipeline

Cardio3 BioSciences receives approval for the continuation of its chart-1 phase III clinical trial from the DSMB

Cardio3 BioSciences receives approval for the continuation of its chart-1 phase III clinical trial from the DSMB